INTRODUCTION {#s1}
============

The telomerase reverse transcriptase (*TERT*) gene encodes the catalytic subunit of telomerase that maintains telomere length. Telomerase activity occurs in more than 90% of cancers \[[@R1]\]. One of the hallmark features of tumor cells, it contributes to their growth advantage and survival, and upregulation of the *TERT* gene is the major mechanism of telomerase activation in human cancer \[[@R2]\]. In breast tumors, *TERT* overexpression was associated with tumor aggressiveness \[[@R3]\] and poor survival after adjuvant \[[@R4]\] and neoadjuvant \[[@R5]\] chemotherapy.

Several molecular events can modify *TERT* expression in cancer cells. Somatic mutations and functional single nucleotide polymorphisms (SNP) in the *TERT* promoter can lead to changes in the expression of the gene \[[@R6]\]. Overexpression of the oncogene *MYC* can directly enhance *TERT* expression by increased binding to the *TERT* promoter \[[@R7]\]. Increased copy number or amplification of the *TERT* gene can also result in *TERT* upregulation \[[@R8]--[@R10]\].

The *TERT* promoter is the most important element of telomerase expression because it harbors binding sites for numerous cellular transcriptional activators and repressors that directly or indirectly regulate gene expression. Recurrent somatic mutations in the *TERT* promoter were found in cancers of the central nervous system (43%), bladder (59%), thyroid (follicular cell-derived, 10%) and skin (melanoma, 29%) \[[@R11], [@R12]\]. In particular, two hotspot C228T and C250T mutations create binding motifs for transcription factor ETS2 and increase *TERT* transcriptional activity \[[@R13]\]. In addition, the T349C SNP, chr5:1,295,349 T\>C (rs2853669) affects telomerase activity and telomere length \[[@R14], [@R15]\]. This polymorphism can be studied in both blood and tumor samples since the results are concordant \[[@R14], [@R16]\].

In breast cancer, only limited data are available concerning the incidence of mutations and SNP in the *TERT* promoter, *TERT* gains and their relationship with *TERT* upregulation and patient prognosis. To address these issues, we investigated the mutational status and genotype of the *TERT* promoter, *TERT* gene copy number and *TERT* and *MYC* mRNA expression in two breast cancer cohorts. The first cohort comprised 77 patients with triple-negative breast cancer (TNBC) from two recent neoadjuvant trials assessing the efficacy and toxicity of anti-EGFR antibodies combined with chemotherapy \[[@R17], [@R18]\]. The patients had been followed for 5 years. The second cohort consisted of a retrospective series of 45 patients treated with standard neoadjuvant chemotherapy (NCT). Most of them had common hormone-positive tumors and had been followed for more than 10 years.

RESULTS {#s2}
=======

*TERT* promoter status {#s2_1}
----------------------

We detected no activating *TERT* promoter mutations, including hotspot mutations C228T and C250T, in 77 pre-NCT breast tumor biopsies (cohort \#1) and 45 post-NCT residual tumors (cohort \#2). The T349C (rs2853669) SNP was identified in 42.3% of tumor biopsies and 48.9% of residual tumors (Table [1](#T1){ref-type="table"}). In both \#1 and \#2 cohorts, most tumors with the variant C allele had a heterozygous 349 T/C genotype (37.2% and 44.4%, respectively) whereas the frequency of 349 C/C homozygotes was low (5.1% and 6.7%). Overall, the frequencies of T349C in the two cohorts were similar to those in the 1000 Genome database for Europe.

###### Distributions of *TERT* promoter rs2853669 alleles (T349C SNP) in breast cancer cohorts (with 95%-confidence intervals) and 1000 genome database

                                     349 T/T              349 T/C              349 C/C
  ---------------------------------- -------------------- -------------------- ------------------
  pre-NCT biopsies (n= 77)           57.7% (46.7-68.7%)   37.2% (26.5-47.9%)   5.1% (1.1-12.3%)
  **Breast cancer cohort \#2**                                                 
  post-NCT residual tumors (n= 45)   48.9% (33.4-63.5%)   44.4% (29.9-58.9%)   6.7% (1.7-18.4%)
  **1000 Genome Database**                                                     
  All populations                    53%                  34.5%                12.5%
  European population                52.1%                38.2%                9.7%

*TERT* copy number aberrations {#s2_2}
------------------------------

We found that *TERT* gains were relatively frequent events in both cohorts. Twenty tumors (25.6%) in cohort \#1 and seven tumors (15.6%) in cohort \#2 had *TERT* gains. *TERT* losses were rare, with the alteration occurring in three tumors (3.9%) in cohort \#1 and two tumors (4.4%) in cohort \#2.

Associations of the T349C genotype and *TERT* gene copy number gains with *TERT* and *MYC* expression {#s2_3}
-----------------------------------------------------------------------------------------------------

We investigated whether T349C genotype and *TERT* gains were associated with changes in the expression of the *TERT* gene (Figure [1A--1B](#F1){ref-type="fig"}). The results were similar in the two cohorts. Tumors with 349 T/C or C/C polymorphism had increased expression of *TERT*, but the difference from the 349 T/T cases was not significant. In contrast, *TERT* gene copy number gains were associated with a highly significant increase in gene expression as compared to cases without *TERT* gain. Of note, *TERT* gains were more frequent in the presence of the T349C SNP. In cases with 349 T/C or C/C genotypes, the relative risk of a *TERT* gain increased 3.2-fold (*P* = 0.0036, 95% confidence interval from 1.5 to 6.9) in cohort \#1 and 5.7-fold in cohort \#2 (*P* = 0.11, 95% confidence interval 1.0-32.0), as compared to the risk in 349 T/T cases.

![The levels of *TERT* and *MYC* gene expression according to T349C status and *TERT* gene copy number in breast cancer cohorts \#1 **(A, C)** and \#2 **(B, D)**. *TERT* gains were associated with a significant increase in *TERT* and *MYC* expression in both cohorts.](oncotarget-08-77540-g001){#F1}

In parallel, we investigated if the presence of *TERT* T349C polymorphism or gain was associated with the expression levels of *MYC* oncogene, a strong positive regulator of *TERT* expression (Figure [1C--1D](#F1){ref-type="fig"}). We found no association between the presence of the T349C SNP and *MYC* expression. In contrast, a significantly higher expression of the *MYC* gene were observed in cases with *TERT* gains (cohort \#1, *P* \< 10^-3^; cohort \#2, *P* = 0.015). Overall, the levels of *TERT* and *MYC* expression were significantly correlated in both cohorts (Pearson *r* = 0.696, *P* \< 10^-7^ in cohort \#1 and *r* = 0.542, *P* \< 10^-3^ in cohort \#2).

Clinical significance of the T349C SNP and *TERT* gene copy number gains {#s2_4}
------------------------------------------------------------------------

The presence of the T349C SNP (349 T/C and C/C genotypes) in cohort \#1 was not significantly associated with clinicopathologic characteristics such as tumor size, tumor grade, nodal status and pathologic response to NCT (Figure [2A](#F2){ref-type="fig"}). However, the rate of incomplete pathologic responses tended to be higher in T349C cases than in patients with T349T (69% vs. 51%, *P* = 0.12). Patients with the T349C genotype had significantly shorter DFS and a trend toward a shorter OS (Figure [2B--2C](#F2){ref-type="fig"}).

![Distribution of clinicopathologic characteristics: tumor size, tumor grade, nodal status and pathologic response **(A)** disease-free **(B)** and overall survival **(C)** in cohort \#1 according to T349C status. Patients with 349 T/C or C/C alleles had significantly shorter DFS and a trend toward a shorter OS.](oncotarget-08-77540-g002){#F2}

In cohort \#2, the T349C SNP was not associated with clinicopathologic characteristics (Figure [3A](#F3){ref-type="fig"}). T3-4 tumors were more frequent in T349C patients than in those with 349 T/T genotype (43% vs 23%), but not to a level of significance (*P* = 0.14). Survival analysis showed, as in cohort \#1, a significant effect of T349C on DFS but not on OS (Figure [3B](#F3){ref-type="fig"}).

![Distribution of clinicopathologic characteristics: tumor size, tumor grade, nodal status and pathologic response **(A)** disease-free **(B)** and overall survival **(C)** in cohort \#2 according to T349C status. Patients with 349 T/C or C/C alleles had significantly shorter DFS but no difference in OS.](oncotarget-08-77540-g003){#F3}

Patients with *TERT* gains in cohort \#1 had a trend toward a higher proportion of SBR grade III tumors (*P* = 0.13) and a significantly higher rate of incomplete pathologic responses (*P* \< 0.01, Figure [4A](#F4){ref-type="fig"}). No association with other clinicopathologic characteristics was observed. Both DFS and OS were significantly shorter in patients with *TERT* gains (Figure [4B--4C](#F4){ref-type="fig"}).

![Distribution of clinicopathologic characteristics: tumor size, tumor grade, nodal status and pathologic response **(A)** disease-free **(B)** and overall survival **(C)** in patients from cohort \#1 with and without *TERT* gene copy number gain. Patients with *TERT* gains had a significantly higher rate of incomplete pathologic responses and significantly shorter DFS and OS.](oncotarget-08-77540-g004){#F4}

In cohort \#2, the number of cases with *TERT* gains was small (n=7) and the distribution of clinicopathological features among cases with and without gains was not significantly different (Figure [5A](#F5){ref-type="fig"}). However, the occurrence of a *TERT* gain was significantly related to shorter DFS and OS (Figure [5B--5C](#F5){ref-type="fig"}).

![Distribution of clinicopathologic characteristics: tumor size, tumor grade, nodal status and pathologic response **(A)** disease-free **(B)** and overall survival **(C)** in patients from cohort \#2 with and without *TERT* gene copy number gain. Patients with *TERT* gains had a significantly higher rate of incomplete pathologic responses and significantly shorter DFS and OS.](oncotarget-08-77540-g005){#F5}

*MYC* expression levels impact the prognostic value of *TERT* gains {#s2_5}
-------------------------------------------------------------------

Univariate Cox analysis for DFS in cohort \#1 showed that the presence of the T349C genotype and *TERT* gain increased significantly the risk of tumor recurrence with HR of 2.8 and 3.8, respectively (Table [2](#T2){ref-type="table"}). High *MYC* expression (\> median) also had a significant and negative effect on DFS (HR of 3.5). Importantly, very high levels of *MYC* expression (upper quartile, \> 421) were associated with a much higher risk of tumor recurrence (HR of 9.4, 95%-CI: 3.2-27.2, *P* \< 0.0001). As expected, incomplete pathologic responses to NCT according to Chevallier\'s classification had a significant negative prognostic effect (HR of 3.6). When adjusted for pathologic responses, *TERT* gain and *MYC* overexpression remained significant prognostic factors (Table [2](#T2){ref-type="table"}). As mentioned above, tumors with *TERT* gain frequently had *MYC* overexpression, and it was assumed that the presence of both abnormalities would confer a worse prognosis. Indeed, the combination of *MYC* overexpression with *TERT* gains was associated with the shortest DFS and OS, whereas lower *MYC* levels annulled any negative effect of *TERT* gain on DFS and OS (Figure [6A--6B](#F6){ref-type="fig"}). In cases without *TERT* gain, *MYC* levels were not prognostic (Figure [6C--6D](#F6){ref-type="fig"}).

###### Cox analysis for disease-free survival in breast cancer cohort \#1

  Parameters                                  Unadjusted       Adjusted\*                    
  ------------------------------------------- ---------------- ------------ ---------------- -------
  *TERT* gain (yes vs no)                     3.8 (1.4-10.3)   0.0078       3.0 (1.1-8.4)    0.032
  *TERT* T349C (yes vs no)                    2.8 (1.0-7.7)    0.047        2.3 (0.9-6.6)    0.096
  *MYC* (high vs low)\*\*                     3.5 (1.1-10.8)   0.031        3.2 (1.1-10.1)   0.045
  Chevallier\'s classification (3-4 vs 1-2)   3.6 (1.1-12.6)   0.048        \-               \-

\*Adjusted for treatment response according to Chevallier\'s classification: incomplete pathologic response, classes 3-4, vs complete pathologic response, classes 1-2.

\*\*High \> median, low [\<]{.ul} median (181)

Hazard ratio, HR; 95% confidence interval, 95% CI.

![The combination of *TERT* gene copy number gains and *MYC* overexpression was associated with the shortest DFS and OS in cohort \#1\
Lower *MYC* levels annulled the negative effect of *TERT* gains on DFS and OS **(A, B)**. In cases without *TERT* gains, *MYC* levels had no effect on patient survival **(C, D)**.](oncotarget-08-77540-g006){#F6}

DISCUSSION {#s3}
==========

Telomerase activation protects malignant cells from apoptosis and senescence by preventing further telomere loss \[[@R2], [@R3], [@R19]\]. Regulation of telomerase activation in cancer is complex and multifactorial and involves transcriptional activation of the *TERT* gene \[[@R10]\].

Activating somatic mutations of the *TERT* promoter have been reported in various cancers \[[@R11], [@R12]\]. The two most common mutations, C228T and C250T, map -124 and -146 bp upstream of the *TERT* ATG site (chr5: 1,295,228 C\>T and 1,295,250 C\>T, respectively) and create binding sites for ETS/TCF transcription factors, which leads to a two- to four-fold increase in transcriptional activity \[[@R13], [@R20]\]. These mutations were not found in limited breast cancer series \[[@R11], [@R12]\]. Our results from a total of 122 breast tumors evidenced no *TERT* promoter mutations, suggesting that this mutational mechanism is not likely to be involved in *TERT* upregulation in breast cancer.

The variant C-allele of the rs2853669 (T349C) polymorphism disrupts an ETS2-binding site (EtsA) in the proximal region of the *TERT* promoter \[[@R14]\]. Although decreased binding of transcription factor ETS2 can modify the expression of the gene, opinions differ on its effect on the level of *TERT* expression in cancer cells. Our results from cases of breast cancer did not show any significant effect of the T349C SNP on *TERT* expression. Previous studies showed an association of the T349C genotype with reduced *TERT* expression in non-small cell lung cancer, bladder cancer and glioblastoma \[[@R16], [@R21], [@R22]\]. However, a recent report on four hepatocellular carcinoma cell lines described increased luciferase *TERT* promoter activity in the presence of the T349C SNP \[[@R23]\]. The T349C variant site is close to (2 bp downstream) the binding site of transcriptional repressor E2F1, and T/C and C/C variants seem to inhibit E2F1 binding to the *TERT* promoter. In the presence of activating *TERT* mutations, this SNP was suggested to enhance *TERT* transcription levels by blocking E2F1 binding to its promoter. These recent findings suggest that the cooperation of native and changed (mutations, SNP) binding sites for multiple transcriptional factors in the *TERT* promoter could regulate *TERT* expression and result in cancer-specific effects of SNP.

There has been much debate about the clinical effect of the T349C SNP on the survival of patients with malignancies. Several studies reported its positive prognostic value in the context of activating *TERT* promoter mutations in bladder cancer and clear cell renal cell carcinoma \[[@R22], [@R24], [@R25]\]. However, more recent reports have shown that this SNP has a negative effect in glioblastoma and liver cancer patients bearing activating *TERT* promoter mutations \[[@R23], [@R26]\]. Among acute myeloid leukemia patients without *TERT* promoter mutations, T349C carriers had significantly shorter survival times \[[@R27]\]. Our study shows for the first time a negative effect of the T349C SNP on survival in breast cancer patients in the absence of activating somatic mutations. However, this SNP was significantly associated with *TERT* copy number gains in our patient series.

Increased *TERT* gene dosage was seen in about 30% of various human tumor-derived cell lines, including breast cancer cells \[[@R28]\]. We found *TERT* copy number gains in more than 20% of primary breast tumors examined. Previous studies yielded conflicting results regarding the effect of *TERT* gain on *TERT* mRNA expression. *TERT* gene gains were associated with higher *TERT* mRNA expression in non-small-cell lung adenocarcinoma and Merkell cell carcinoma \[[@R29], [@R30]\] and with high TERT protein expression in breast cancer and cervical carcinomas \[[@R28], [@R31]\]. However, no significant association was found in colorectal carcinomas and squamous-cell lung cancer \[[@R30], [@R32]\]. Our observation of a highly positive correlation between the *TERT* gene copy number and its mRNA level suggests that *TERT* gain has a functional effect on *TERT* transcription in breast cancer.

We showed that *TERT* gains identified in pre-NCT biopsies were predictive of incomplete pathological responses and shorter survival. In addition, *TERT* gain was a significant predictor of worse survival when assessed in residual post-NCT tumors. To our knowledge, only two studies have reported a negative effect of *TERT* gains on survival in non-small cell lung carcinomas and melanomas \[[@R30], [@R33]\]. For the first time, we show that *TERT* gain is also a negative prognostic marker associated with higher risk of disease recurrence or death from breast cancer and could potentially be used to adapt treatment strategies.

*TERT* upregulation correlates with increased telomerase activity. Inhibition of telomerase in breast tumors might potentiate the effects of standard anti-cancer treatments \[[@R34]\]. This opens up the perspective of using telomerase inhibitors in patients resistant to NCT. Preclinical studies with the telomerase inhibitor GRN163L showed that it can restore sensitivity of HER2+ breast cancer cell lines to trastuzumab and so patients with HER2+ breast cancers were recruited into a phase I clinical trial (NCT 01265927). In combination with chemotherapy, GRN163L was used in a phase II clinical trial in patients with locally recurrent or metastatic breast cancer (NCT01256762). These clinical trials have been completed but the study results are not yet available \[[@R34]\].

Telomerase reactivation and/or *TERT* upregulation correlate with *MYC* overexpression \[[@R35], [@R36]\]. In line with these findings, we observed that *MYC* and *TERT* expression levels are significantly correlated. MYC is a primary transcription factor of the *TERT* gene and stimulates its promoter activity \[[@R37], [@R38]\]. In breast cancer cells, MYC binds to an ETS2 site (EtsA) in the *TERT* gene promoter and increases *TERT* expression levels \[[@R15]\]. As mentioned above, this binding site is disrupted by T349C variants, but we observed no significant changes in *TERT* or *MYC* expression according to the presence or absence of this SNP. In contrast, *MYC* overexpression was strongly associated with the presence of *TERT* gains. Interestingly, a recent study showed that TERT regulates MYC ubiquitination, stabilization and binding to its target gene promoters \[[@R39]\]. This feed-forward transcriptional loop between MYC and TERT is functionally critical for oncogenesis. In our study, we found that *MYC* overexpression often coincided with *TERT* gains. Enhanced MYC stability and function in cells with high TERT and MYC levels could potentiate MYC-dependent oncogenesis.

By combining the data on *TERT* gain and *MYC* overexpression we were able to isolate a particularly bad prognosis subgroup of breast cancer patients. MYC is considered to promote tumor cell survival, proliferation and progression in breast cancer \[[@R40], [@R41]\] and regulates the expression of 13 different poor-outcome cancer signatures \[[@R42]\]. We found that *MYC* overexpression had a negative prognostic value in the whole patient population and a particularly significant effect within the subgroup of patients with *TERT* gains. A concomitant upregulation of *TERT* and *MYC* identified patients with a high risk of breast cancer recurrence. In contrast, lower *MYC* expression levels were associated with a favorable prognosis, despite the presence of *TERT* gains.

In conclusion, we found no activating *TERT* promoter mutations in 122 breast cancer patients. The T349C *TERT* promoter SNP was not significantly associated with *TERT* expression but T349C carriers had shorter survival. Notably, *TERT* gene copy number gain was significantly related to *TERT* upregulation and, in association with *MYC* overexpression, characterized particularly aggressive disease. These results show a significant effect of gene copy number gain on *TERT* expression level and provide a new insight into the clinical significance of *TERT* and *MYC* upregulation in breast cancer.

MATERIALS AND METHODS {#s4}
=====================

Patients and samples {#s4_1}
--------------------

Cohort \#1 comprised 77 patients with operable, stage II--III TNBC enrolled in two neoadjuvant trials evaluating the efficacy and toxicity of anti-EGFR antibodies plus chemotherapy: panitumumab combined with a standard neoadjuvant anthracycline/taxane-based \[[@R17]\] and cetuximab combined with docetaxel \[[@R18]\]. After NCT, pathologic complete responses (classes 1 and 2 according to Chevallier\'s classification) were observed in 32 of 77 cases (41.6%). The remaining 45 (58.4%) patients had incomplete pathologic responses (class 3, N = 39 and class 4, N = 6). The median follow-up in this cohort was 3.8 years (range, 0.9-5.5 years). During follow-up, 16 (20.8%) patients relapsed and 11 (14.3%) died from breast cancer. Cohort \#2 consisted of archived samples of residual post-NCT tumors from 45 women diagnosed with invasive breast cancer and treated with NCT protocols \[[@R43]\] between 1996 and 2010 at the Jean Perrin Cancer Center (Clermont-Ferrand, France). Following NCT, patients underwent appropriate surgery and radiotherapy. Those with important residual disease received adjuvant chemotherapy. Menopausal patients with hormone receptor-positive tumors received tamoxifen for 5 years. The mean follow-up was 9.1 years (range, 1.1-15.9 years). During this period, 20 (44.4%) patients relapsed and 14 (31.1%) died from breast cancer. In cohort \#1, the study was performed on pre-treatment tumor biopsies and in cohort \#2 on post-NCT residual tumor samples cryopreserved in the Biological Resources Center BB-0033-00075. DNA and RNA were simultaneously extracted with the AllPrep DNA/RNA/miRNA Universal Kit (Qiagen, Courtaboeuf, France) according to the manufacturer\'s instructions. The study was approved by the institutional review board.

Gene expression analysis {#s4_2}
------------------------

Total RNA was converted to cDNA by reverse transcription with Superscript II reverse transcriptase (Invitrogen, Cergy-pontoise, France) according to the manufacturer\'s instructions. The expression of *TERT* was quantified by real-time RT-PCR in the Lightcycler 480 System (Roche Diagnostics, Meylan, France) as described previously \[[@R44], [@R45]\]. *MYC* was quantified with primers described in the literature \[[@R46]\]. The normalized copy numbers were expressed as the ratio between transcript copy numbers of the target and control (*B2M*) genes multiplied by 100.

*TERT* promotor sequencing {#s4_3}
--------------------------

The amplification of genomic DNA for the *TERT* promoter region (267 pb) was performed with the following primers: forward 5'-CCGGGCTCCCAGTGGATT-3' and reverse 5'-TTCCCACGTGCGCAGCAG-3'. PCR conditions consisted of an initial heating at 95°C for 15 minutes followed by 40 cycles at 95°C for 30 seconds, 60°C for 20 seconds and 72°C for 30 seconds. Amplified PCR products were sequenced with BigDye v1.1 on the ABI 3500 Genetic Analyzer (Applied Biosystems, Courtaboeuf, France).

*TERT* copy number quantification {#s4_4}
---------------------------------

*TERT* gene copy number was quantified by Quantitative Multiplex Fluorescent Polymerase Chain Reaction (QMF-PCR) analysis. QMF-PCR was performed on a TProfessional thermocycler (Biometra, Archamps, France) as previously described \[[@R47], [@R48]\]. Primers were designed for three fragments of the *TERT* gene on chromosome 5p (5'UTR, Exon 9 and 3'UTR) to cover the entire gene. The 5'UTR region is very GC-rich and was difficult to amplify. We therefore had to limit the analysis to exon 9 and 3'UTR. Seven genes on chromosomes 2p, 4p, 7q, 10q 11p, 11q (*PVRL1, BOD1L, RET, ZNF638, AGBL2, CFTR* and *POR*) were co-amplified as controls. Primers and technical details are described in Supplementary Methods. The fluorescence intensities of PCR products were correlated with the copy number of the relevant exons. Fourteen control DNAs were included in each experiment: 12 normal DNAs and 3 DNAs with known *TERT* copy number (loss, normal and gain, as determined by array-comparative genomic hybridization). A dosage quotient was calculated relative to all the other amplified exons in patients and controls. The range of ratios corresponding to two copies of *TERT* gene was set between 0.8 and 1.2 (mean +/- 3 standard deviations of values obtained in normal DNA samples). Ratios \> 1.2 were considered as gains and \< 0.8 as losses.

Statistical analysis {#s4_5}
--------------------

Standard tests (Kruskal-Wallis H test, ANOVA, Student\'s t-test, chi-squared test, Pearson\'s correlation) were used to study the relationship between characteristics. Disease-free survival (DFS) was measured from diagnosis until the first relapse (local or distant) and overall survival (OS) from the start of NCT until the last follow-up report. Survival curves were established by the Kaplan-Meier method and compared with the log-rank test.

SUPPLEMENTARY MATERIALS FIGURES AND TABLES {#sup1}
==========================================
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